Source: Annual Congress 2002 - Thoracic oncology: biology
Disease area: Thoracic oncology

Abstract

HER-2/neu overexpression is found in more than 20% of non-small cell lung cancer (NSCLC) and is associated with a poor prognosis; however, in breast cancer, HER-2/neu overexpression predicts response to antibody against HER-2/neu, Trastuzumab. Trastuzumab cytotoxicity for NSCLC cell lines supported clinical testing in HER-2/neu overexpressing NSCLCs. In the large proportion of unresectable NSCLCs, howewer, only small bioptic or cytologic samples can be available for immunohistochemical evaluation of HER-2/neu. To assess if HER-2/neu expression in small bioptic samples is representative of the whole tumor, we compared HER-2/neu expression in 26 paired NSCLC bioptic and surgical samples. HER-2/neu immunohistochemical evaluation was performed on formalin-fixed, routinely processed sample sections after microwave oven pretreatment in citrate buffer pH 6, with CB11 monoclonal antibody (Novocastra,UK). Membrane stain intensity and pattern were scored according to the scale approved for breast carcinoma.
Seventeen biopsies and 20 surgical samples did not overexpress HER-2/neu (0, 1+ scores); 6 biopsies and 4 surgical samples scored 2+; 3 biopsies and 2 surgical samples scored 3+. Biopsy and surgical sample concordance was recorded in 23 cases (88%, 6 positive and 17 negative). Three discordant pairs comprised a positive biopsy and a negative surgical sample.
On the basis of these data, the expression of HER-2/neu in bioptic NSCLC samples can be considered to reliably represent the whole tumor mass. The small proportion of overexpressing biopsies with negative surgical samples could be the consequence of different tumor clones prevailing in endobronchial and peripheral tumor areas.

Rating:

Share or cite this content

Citations should be made in the following way:
C. Nascimbene, T. Oggionni, P. Morbini, P. Vitulo, A. Cascina, A. Rossi, U. Magrini (Pavia, Italy). HER-2/neu expression in bioptic and surgical samples of non small cell lung carcinoma. Eur Respir J 2002; 20: Suppl. 38, 142

Member's Comments

No comment yet.

Related content which might interest you: Correlation of P53 and CerbB-2 expression in the diagnostic biopsies and the corresponding resected tumors in non small cell lung caner Source: Eur Respir J 2004; 24: Suppl. 48, 43s Year: 2004 Her-2/neu expression in advanced non small cell lung carcinomas Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens Source: Eur Respir Rev, 26 (144) 170007; 10.1183/16000617.0007-2017 Year: 2017 PD-L1 determination in cytological and histological samples in patients with non-small cell lung cancer Source: International Congress 2018 – Linear and radial EBUS and peripheral nodules Year: 2018 HER-2/neu overexpression in patients with lung carcinoma Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003 Evaluation by immunohistochemistry of EGF-R expression before and after chemotherapy in non small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Accuracy of PD-L1 tumour staining of cytological and histological samples of lung adenocarcinoma Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Hypermethylation pattern in genomic DNA samples derived from tumor and serum of resected non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Interobserver agreement in determining non-small cell lung cancer subtype in specimens acquired by EBUS-TBNA}, Source: Eur Respir J 2012; 40: 699-705 Year: 2012 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer Source: Eur Respir J 2015; 46: 1541-1543 Year: 2015 Correlation of p53, EGFR and HER2 expression in the diagnostic biopsies and the corresponding resected tumours in NSCLC Source: Eur Respir J 2003; 22: Suppl. 45, 198s Year: 2003 KI67: Analysis of its expression and prognostic significance in a resected non small cell lung cancer population Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 An analysis of EGFR expression and tumour imaging in non-small cell carcinomas of lung Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Pathology and immunohistochemistry of lung cancer Source: Eur Respir Mon; 2009: 44: 15–35 Year: 2009 Expression of protein onkological marker onkoprobe in peripheral blood in cases of tracheal invasion and lung metastases of thyroid carcinoma Source: Eur Respir J 2002; 20: Suppl. 38, 466s Year: 2002 CD44v6 expression in tissue of patients with lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 Histological subtyping of non-small cell lung cancer using transbronchial biopsy specimens obtained with a small forceps Source: International Congress 2017 – How to reach peripheral lesions: (radial EBUS, CLE, navigation, etc.) and treat airleaks Year: 2017